<?xml version="1.0" encoding="UTF-8"?>
<p id="p0210">The clinical usefulness of the capsid binding antivirals pleconaril, vapendavir, and pocapavir against RVs still has to be shown. A high likelihood for drug resistances limits their clinical applicability (
 <xref rid="bb0095" ref-type="bibr">Papadopoulos et al., 2017</xref>).
</p>
